ArticleArchivos de cardiologia de Mexico2022
Validation of medical prescriptions’ suitability on patients with heart disease
Article in Archivos de cardiologia de Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Give pharmacotherapeutic following and study the variability and suitability of medical prescriptions given to patients during their hospitalization, through optimal and individualized pharmaceutical attention, that allows the best treatment stablished for each patient. Method: Data was captured prospectively, descriptively, and longitudinally with the purpose of analyzing the treatment’s suitability in patients with heart disease, through their pharmacotherapeutic following. Results: The pharmacotherapeutic evaluation of a population of 1,228 subjects proved that elderly male patients with multiple comorbidities and in polypharmacy are more susceptible of presenting severe drug interactions (65%) and prescription errors (14.4%). Conclusions: It is essential to have a specialized pharmacist within a multi-disciplinary medical team who manages the validation of each prescription’s suitability, making pharmaceutical interventions which allows the early detection of drug interactions and prescription errors, minimizing the probability of presenting real side effects and ensuring the effectiveness and security of the medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.